Literature DB >> 27126645

Global Burden of Thrombosis: Epidemiologic Aspects.

Aaron M Wendelboe1, Gary E Raskob2.   

Abstract

Thromboembolic conditions were estimated to account for 1 in 4 deaths worldwide in 2010 and are the leading cause of mortality. Thromboembolic conditions are divided into arterial and venous thrombotic conditions. Ischemic heart disease and ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism. Atrial fibrillation is a major risk factor for stroke and systemic arterial thromboembolism. Estimates of the global burden of disease were obtained from Global Burden of Disease Project reports, recent systematic reviews, and searching the published literature for recent studies reporting measures of incidence, burden, and disability-adjusted life-years. Estimates per 100 000 of the global incidence rate (IR) for each condition are ischemic heart disease, IR=1518.7; myocardial infarction, IR=139.3; ischemic stroke, IR=114.3; atrial fibrillation, IR=77.5 in males and 59.5 in females; and venous thromboembolism, IR=115 to 269. Mortality rates (MRs) for each condition are ischemic heart disease, MR=105.5; ischemic stroke, MR=42.3; atrial fibrillation, MR=1.7; and venous thromboembolism, MR=9.4 to 32.3. Global public awareness is substantially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and stroke (85%). Over time, the incidence and MRs of these conditions have improved in developed countries, but are increasing in developing countries. Public health efforts to measure disease burden and increase awareness of symptoms and risk factors need to improve, particularly in low- and middle-income regions to address this leading cause of morbidity and mortality.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; myocardial infarction; pulmonary embolism; stroke; venous thromboembolism

Mesh:

Year:  2016        PMID: 27126645     DOI: 10.1161/CIRCRESAHA.115.306841

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  158 in total

1.  Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.

Authors:  Holly Guy; Vicki Laskier; Mark Fisher; W Richey Neuman; Iwona Bucior; Steven Deitelzweig; Alexander T Cohen
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

2.  Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).

Authors:  Behnood Bikdeli; David Jimenez; Mayra Hawkins; Salvador Ortíz; Paolo Prandoni; Benjamin Brenner; Hervé Decousus; Frederick A Masoudi; Javier Trujillo-Santos; Harlan M Krumholz; Manuel Monreal
Journal:  Thromb Haemost       Date:  2018-01-05       Impact factor: 5.249

3.  Rapid assembly and profiling of an anticoagulant sulfoprotein library.

Authors:  Emma E Watson; Jorge Ripoll-Rozada; Ashley C Lee; Mike C L Wu; Charlotte Franck; Tim Pasch; Bhavesh Premdjee; Jessica Sayers; Maria F Pinto; Pedro M Martins; Shaun P Jackson; Pedro José Barbosa Pereira; Richard J Payne
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-20       Impact factor: 11.205

Review 4.  Antithrombotic dose: Some observations from published clinical trials.

Authors:  Simon B Dimmitt; Christopher N Floyd; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-07-01       Impact factor: 4.335

Review 5.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

6.  Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome.

Authors:  Valerio De Stefano
Journal:  Haematologica       Date:  2018-09       Impact factor: 9.941

7.  Silencing of microRNA-494 inhibits the neurotoxic Th1 shift via regulating HDAC2-STAT4 cascade in ischaemic stroke.

Authors:  Haiping Zhao; Guangwen Li; Rongliang Wang; Zhen Tao; Qingfeng Ma; Sijia Zhang; Ziping Han; Feng Yan; Fangfang Li; Ping Liu; Shubei Ma; Xunming Ji; Yumin Luo
Journal:  Br J Pharmacol       Date:  2019-11-08       Impact factor: 8.739

8.  Differential sensitivity of various markers of platelet activation with adenosine diphosphate.

Authors:  Giang Le Minh; Alina D Peshkova; Izabella A Andrianova; John W Weisel; Rustem I Litvinov
Journal:  Bionanoscience       Date:  2018-12-10

Review 9.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

10.  Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer.

Authors:  Romualdo Troisi; Valeria Napolitano; Vera Spiridonova; Irene Russo Krauss; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.